Michael Harrington to Carcinoma, Merkel Cell
This is a "connection" page, showing publications Michael Harrington has written about Carcinoma, Merkel Cell.
Connection Strength
0.481
-
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. J Immunother Cancer. 2026 Jan 14; 14(1).
Score: 0.242
-
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2026 Jan; 33(1):389-396.
Score: 0.239